169 related articles for article (PubMed ID: 10333228)
1. Progression-related expression of beta3 integrin in melanomas and nevi.
Van Belle PA; Elenitsas R; Satyamoorthy K; Wolfe JT; Guerry D; Schuchter L; Van Belle TJ; Albelda S; Tahin P; Herlyn M; Elder DE
Hum Pathol; 1999 May; 30(5):562-7. PubMed ID: 10333228
[TBL] [Abstract][Full Text] [Related]
2. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
3. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
4. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression.
Moretti S; Pinzi C; Berti E; Spallanzani A; Chiarugi A; Boddi V; Reali UM; Giannotti B
Melanoma Res; 1997 Aug; 7(4):313-21. PubMed ID: 9293481
[TBL] [Abstract][Full Text] [Related]
5. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study.
Feinmesser M; Veltman V; Morgenstern S; Tobar A; Gutman H; Kaganovsky E; Tzabari C; Sulkes J; Okon E
Am J Dermatopathol; 2010 Oct; 32(7):665-75. PubMed ID: 20559114
[TBL] [Abstract][Full Text] [Related]
6. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
Krengel S; Grotelüschen F; Bartsch S; Tronnier M
J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
[TBL] [Abstract][Full Text] [Related]
7. DEK expression in melanocytic lesions.
Kappes F; Khodadoust MS; Yu L; Kim DS; Fullen DR; Markovitz DM; Ma L
Hum Pathol; 2011 Jul; 42(7):932-8. PubMed ID: 21316078
[TBL] [Abstract][Full Text] [Related]
8. IMP-3 expression in melanocytic lesions.
Yu L; Xu H; Wasco MJ; Bourne PA; Ma L
J Cutan Pathol; 2010 Mar; 37(3):316-22. PubMed ID: 19788446
[TBL] [Abstract][Full Text] [Related]
9. IMP-3 is a novel progression marker in malignant melanoma.
Pryor JG; Bourne PA; Yang Q; Spaulding BO; Scott GA; Xu H
Mod Pathol; 2008 Apr; 21(4):431-7. PubMed ID: 18204432
[TBL] [Abstract][Full Text] [Related]
10. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
[TBL] [Abstract][Full Text] [Related]
11. TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas.
Lyle S; Salhany KE; Elder DE
Mod Pathol; 2000 Jan; 13(1):52-5. PubMed ID: 10658910
[TBL] [Abstract][Full Text] [Related]
12. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
[TBL] [Abstract][Full Text] [Related]
13. Melanoma-associated expression of transforming growth factor-beta isoforms.
Van Belle P; Rodeck U; Nuamah I; Halpern AC; Elder DE
Am J Pathol; 1996 Jun; 148(6):1887-94. PubMed ID: 8669474
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
15. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
16. The use of elastin immunostain improves the evaluation of melanomas associated with nevi.
Kamino H; Tam S; Tapia B; Toussaint S
J Cutan Pathol; 2009 Aug; 36(8):845-52. PubMed ID: 19032378
[TBL] [Abstract][Full Text] [Related]
17. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
18. Beta3 integrin expression in melanoma predicts subsequent metastasis.
Hieken TJ; Farolan M; Ronan SG; Shilkaitis A; Wild L; Das Gupta TK
J Surg Res; 1996 Jun; 63(1):169-73. PubMed ID: 8661192
[TBL] [Abstract][Full Text] [Related]
19. JARID1B expression in human melanoma and benign melanocytic skin lesions.
Kuźbicki L; Lange D; Strączyńska-Niemiec A; Chwirot BW
Melanoma Res; 2013 Feb; 23(1):8-12. PubMed ID: 23262439
[TBL] [Abstract][Full Text] [Related]
20. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.
Sparrow LE; Eldon MJ; English DR; Heenan PJ
Am J Dermatopathol; 1998 Jun; 20(3):255-61. PubMed ID: 9650698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]